CDKN2B and neoplasm: Adjacent tumour suppressor pairs (e.g., CDKN2A/CDKN2B, BIRC2/BIRC3, HELQ/FAM175A, ...) may be especially rewarding targets for homozygous deletion in some cases, as two mutation events can abolish all tumour suppressor activity.